Vertex Pharmaceuticals (CHIX:VX1D) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VX1D Vertex Pharmaceuticals Inc CHIX:VX1D
86 GF Score
Price €322.40
GF Value €335.38
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:VX1D
86GF Score
Vertex Pharmaceuticals Inc CHIX:VX1D
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vertex Pharmaceuticals (CHIX:VX1D) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €322.40 is trading 3.9% below its estimated GF Value™ of €335.38.

Key valuation signals for CHIX:VX1D:

  • FFO:
  • GF Value™: €335.38 vs. price of €322.40 (3.9% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the CHIX:VX1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score

Get the complete analysis for CHIX:VX1D

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€322.40
Price
€335.38
GF Value